Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 TSX Penny Stocks With Market Caps Under CA$30M To Consider

In This Article:

The Canadian market, like its U.S. counterpart, has been experiencing a notable upswing following the recent decisive election outcome in the United States, which has cleared a significant source of uncertainty for investors. Amid this backdrop of shifting political landscapes and economic fundamentals, penny stocks continue to capture interest as potential investment opportunities due to their affordability and growth potential. While the term "penny stocks" may seem outdated, these investments often represent smaller or newer companies that can offer unique chances for growth when backed by strong financial health.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

PetroTal (TSX:TAL)

CA$0.67

CA$593.32M

★★★★★★

Amerigo Resources (TSX:ARG)

CA$1.67

CA$285.18M

★★★★★☆

Alvopetro Energy (TSXV:ALV)

CA$4.91

CA$180.11M

★★★★★★

Pulse Seismic (TSX:PSD)

CA$2.30

CA$117.56M

★★★★★★

Findev (TSXV:FDI)

CA$0.425

CA$11.75M

★★★★★☆

Mandalay Resources (TSX:MND)

CA$3.31

CA$316.75M

★★★★★★

Winshear Gold (TSXV:WINS)

CA$0.155

CA$5.03M

★★★★★★

Foraco International (TSX:FAR)

CA$2.22

CA$228.59M

★★★★★☆

NamSys (TSXV:CTZ)

CA$1.13

CA$30.62M

★★★★★★

Vox Royalty (TSX:VOXR)

CA$3.65

CA$189.71M

★★★★★★

Click here to see the full list of 961 stocks from our TSX Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

MediPharm Labs

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: MediPharm Labs Corp. is a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally with a market cap of CA$26.72 million.

Operations: The company generates CA$37.76 million in revenue from the production and sale of cannabis extracts and derivative products.

Market Cap: CA$26.72M

MediPharm Labs, with a market cap of CA$26.72 million, is navigating the challenges of being unprofitable but has maintained a stable cash runway for over three years based on current free cash flow. Despite negative return on equity and increased losses over the past five years, the company forecasts revenue growth at 28.85% annually. Recent leadership changes see co-founder Keith Strachan transitioning to the board while maintaining strategic influence. The company reported modest revenue increases in recent quarters and remains debt-free, offering some financial stability amid shareholder dilution concerns and ongoing profitability challenges.